Latest News
UK Biotech MiroBio Agrees to USD 405m Gilead Sciences Buyout
Friday 05 August 2022

UK-based biotechnology company MiroBio Ltd has entered into a definitive agreement with US-based Gilead Sciences (NASDAQ: GILD), Inc. to be acquired for approximately USD 405m in cash, subject to customary adjustments, the firm said.

MiroBio is focused on restoring immune balance with agonists targeting immune inhibitory receptors.

MiroBio was spun out of the University of Oxford in 2019 to develop a new class of medicines, called immune checkpoint agonists, to treat autoimmune diseases by restoring balance to the immune system.

Oxford Science Enterprises and Samsara BioCapital co-led a GBP 27m series A investment in 2019 and Medicxi invested in the company in June 2022 when it led an GBP 80 m series B financing.

Nick Williams, who was recently appointed as Partner at Medicxi, oversaw the investment and joined MiroBio's board.

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum.

Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need.

MiroBio is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune balance in autoimmune patients.

MiroBio has developed I-ReSToRE, a proprietary discovery platform, combining its Checkpoint Atlas, a cutting-edge receptor mapping database and visualization tool, with proprietary antibody engineering.

It was spun out of Oxford University in 2019 and is based on more than 15 years of foundational research from the labs of Professor Simon Davis and Professor Richard Cornall with the potential to create safer and more efficacious medicines for patients with autoimmune disease.

MiroBio is backed by a group of international investors including Oxford Science Enterprises, Samsara BioCapital, SR One, Medicxi, Advent Life Sciences, OrbiMed and Monograph.
Details
Date Published: 05/08/2022

Options